High materiality8/10
Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley
Why it may matterVerify against the original reporting
Upside potential supported by higher target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley raises KYMR target to $135; current price is $104.96.
- Morgan Stanley raises KYMR to $135
Key facts
- 01
Target: $135
- 02
Posted price: $104.96
- 03
Analyst firm: Morgan Stanley
- 04
Analyst: Judah Frommer
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.